Intelligence / Healthtech / New Clinical Trials / Gilead Sciences
Clinicaltrial registered2 Nov 2026
Gilead Sciences
2 Nov 2026: Trial registered · Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 2 Nov 2026
- Title
- Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV
- Conditions
- HIV-1 Infection
- Phase
- Phase 4
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07908446
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Gilead Sciences
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Gilead Sciences in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.